“The results of the study are very good,” says Vicente Estrada, head of the Infectious Diseases Service of the Hospital Clínico-San Carlos de Madrid and one of the two coordinators of the phase I / II trial carried out with plitidepsin (aplidine) on 45 patients from 13 Spanish hospitals.
Therefore, he is confident that the phase III trial will start shortly. In a situation where we have nothing except remdesivir and dexamethasone, which have a limited effect, ‘it is necessary to test the potency of this drug in patients», He says. In his opinion, the Medicines Agency should “” expedite the phase III clinical trial. “
This study will try to demonstrate the superiority of plitidepsin in combination with remdesivir and dexamateson in front of